Regenxbio (RGNX) Tops Q4 EPS by 14c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($0.20), $0.14 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $1.23 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'
• Taylor Devices (TAYD) Misses Q4 EPS by 31c